GET DAILY SIGNALSJohnson & Johnson (JNJ): A Diversified Healthcare Leader Worth Watching
Key Takeaways
- Johnson & Johnson is a global healthcare company spanning pharmaceuticals and medical technology.
- The company operates through two main segments: Innovative Medicine and MedTech.
- Its consumer health division was spun off in 2023 into a separate company, KVUE.
- JNJ is a component of the Dow Jones Industrial Average and is widely followed for its scale and diversification.
- Investors track JNJ for its established brands, research pipeline, and defensive, healthcare-oriented business profile.
Introduction
Johnson & Johnson (JNJ) ranks among the world’s largest and most diversified healthcare companies. With origins stretching back more than a century, it develops, manufactures, and sells a wide array of pharmaceutical treatments and medical devices used in hospitals, clinics, and homes globally. Its profile reflects a business grounded in scientific innovation, strong brand recognition, and reach across the healthcare value chain.
Healthcare demand tends to hold steady through economic cycles, so in my view JNJ often serves as a defensive holding in equity portfolios. Its scale, global footprint, and long track record of product development position it as a benchmark name for investors seeking healthcare sector exposure.
Company Background and Operations
Johnson & Johnson was founded in 1886 by Robert Wood Johnson and his brothers in New Brunswick, New Jersey. It started with sterile surgical dressings and later grew into consumer products, pharmaceuticals, and medical devices. Headquarters remain in New Brunswick, with facilities and subsidiaries operating worldwide.
The current business model centers on two primary segments. Innovative Medicine, formerly the pharmaceutical division, develops and markets prescription medicines in areas such as oncology, immunology, neuroscience, cardiovascular disease, and infectious diseases. This segment drives the largest share of revenue. MedTech covers medical devices and technologies for surgery, orthopedics, vision care, and interventional procedures, ranging from surgical instruments and implants to contact lenses and wound-care solutions.
For decades the company also ran a sizable consumer health business. In 2023 that unit became the independent public company Kenvue (KVUE), allowing JNJ to focus on pharmaceuticals and medical technology. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Brands, Markets, and Investor Appeal
Johnson & Johnson has long been linked with familiar consumer brands such as Tylenol, Band-Aid, Neutrogena, and Johnson’s Baby. Although the consumer division now stands alone under Kenvue, the Johnson & Johnson name continues to carry weight in healthcare. In pharmaceuticals and MedTech the company competes with other major players through research and development, regulatory expertise, and global distribution.
JNJ serves patients, providers, hospitals, and governments across markets worldwide, with substantial revenue from the United States and other developed economies plus growing exposure in emerging markets. Its financial profile features significant revenue scale, diversified product lines, and steady research and development investment. The broad portfolio reduces dependence on any single product or therapy area.
Investors follow JNJ for its diversified model that spans pharmaceuticals and medical devices, helping balance risks across categories. Its history of dividend payments and inclusion in the Dow Jones Industrial Average make it a recognized name for both individual and institutional investors. The research pipeline and innovation in Innovative Medicine, combined with MedTech benefits from aging demographics and rising procedure demand, support long-term growth drivers.
Risks to Consider
Despite its scale, Johnson & Johnson faces notable risks. The pharmaceutical industry contends with intense competition, pricing pressure, regulatory oversight, and patent expirations that can erode revenue from established drugs. The MedTech business encounters similar competitive pressures, hospital purchasing cycles, and technological shifts.
The company has dealt with substantial litigation involving certain products, including talc-based powders and opioid-related claims. Legal and regulatory outcomes can create financial and reputational uncertainty. Macroeconomic factors such as foreign exchange fluctuations and healthcare policy changes in key markets can also affect results. Investors should weigh these elements against the company’s diversification when assessing its risk profile.
Integrating AI Tools Into Research
When evaluating names like JNJ I often rely on Tickeron’s AI Screener to quickly compare fundamentals, technical indicators, and industry peers. The platform helps surface ideas that align with specific strategies without replacing personal judgment. In my experience it streamlines the process of reviewing a single stock or an entire sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JNJ in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What are the Contribution Deadlines for My Self-Employed 401(k)?
What are Investment Ideas?
What Is a Chartered Retirement Planning Counselor (CRPC)?
Weekly Market Insights: Record Levels and AI-Powered Trading Strategies
Tickeron Releases New Line of AI Trading Bots - Stock Pickers with Positive Alphas
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement